Genome Canada’s Disruptive Innovations in Genomics (DIG)

This competition is closed. All submitted proposals will be assessed according to the process outlined in the competition timeline, and results will be announced as indicated.

Please feel free to download and/or view the Genome Canada’s Disruptive Innovations in Genomics (DIG) slides. Share it with your colleaguesOn June 11, 2015 Genome Canada launched a Request for Applications (RFA) seeking proposals for research projects which focus on Disruptive Innovations in Genomics.

For the purposes of this competition, a Disruptive Innovation must be either a new genomics technology or the application of an existing technology from another field, applied to the field of genomics. The Innovation must be truly transformative in that it has the potential to either displace an existing technology, disrupt an existing market or create a new market. A Disruptive Innovation offers the capability to do things not previously possible and is not an incremental improvement of an existing technology.

This competition aims to support projects focused on early-stage feasibility studies (Phase 1 projects) and prototype development (Phase 2 projects). Phase 1 and Phase 2 will be run in parallel and a second round of Phase 2 funding, open only to eligible Phase 1 projects, will be available 18 months after successful Phase 1 projects are launched. This will allow Phase 1 projects approved for Phase 2 funding to continue to Phase 2 without a gap in funding, and for projects not approved for Phase 2 funding to wind down.

All applicants must demonstrate, with supporting evidence, the potential for the innovation to be disruptive, have impact within the technology space, and eventually benefits to Canada. In addition, Phase 2 projects must have clear deliverables that will be realized by the end of the project and a plan which explains the next steps of how the deliverables from the research will be transferred, disseminated, used, and/or applied to realize the benefits.

In order to better prepare Ontario-led projects for this competition, OGI will do an initial eligibility assessment of registrations and will coordinate an external review of eligible applications prior to submission to Genome Canada. Please note that to accommodate this process the deadlines for submission to OGI differ from those in the official RFA from Genome Canada. Eligible applicants will receive feedback on their applications including gaps and areas for improvement.

Researchers in Ontario intending to submit an application are strongly encouraged to contact OGI to discuss details of the competition such as the scope, the application process, and co-funding requirements.

Funding Available:

There is approximately $15 million available for this competition from Genome Canada. Please see the table below for the funding breakdown and co-funding requirements:

Phase 1 Phase 2
Genome Canada Funding Available Approx.
$5 M
$10 M
Co-funding Not required At least two thirds
of project budget
Genome Canada Investment
per Project (Maximum)
$250,000 $1 M
Term of Project (Maximum) Two years Three years

Application Material and Relevant Links:

RFA and guidelines:
Request for Applications (RFA)
Guidelines for Funding Research Projects

Registration form:
DIG Registration Form
Please submit registrations to

Full Application forms:
DIG Application Form Phase1
DIG Application Form Phase2
Budget template(Phase 2 only)

Other resources:
Genome Canada Competition webpage link

Competition Timeline

*If you missed the Draft Registration deadline and are still interested in submitting a Registration, please contact

Date Activity
August 5, 2015 * Draft Registrations due to OGI (signatures not required)
September 2, 2015 Final Registrations due to OGI (submit to
September 4, 2015 Final Registrations due to Genome Canada
September 28, 2015 Draft Applications due to OGI
October 22, 2015 Final Applications due to OGI
October 29, 2015 Final Applications due to Genome Canada

For further information about this competition, please contact Meredith McLaren, Manager, Research and Business Development at